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Hematopoietic Stem Cell Transplantation in Children with 
Leukemia: A Single Institution Experience with Respect to 
Donors
Aim of this study was to compare the outcomes of transplantation by donor source and to 
help select the best alternative donor in children with leukemia. Donor sources included 
matched related donor (MRD, n = 35), allele-matched unrelated donor (M-UD, n = 10) or 
-mismatched (MM)-UD (n = 13) or unrelated umbilical cord blood (UCB, n = 11). UCB 
group had a significantly higher incidence of grade II-IV acute graft versus host disease 
(MRD, 11.8%; M-UD, 30.0%; MM-UD, 15.4%, UCB, 54.4%, P = 0.004) but there was 
no difference in incidence of chronic graft versus host disease between 4 groups. The 5-yr 
leukemia-free survival (LFS) was 76.7%, 60.0%, 69.2%, and 45.5%, respectively 
(P = 0.128). MRD group showed higher LFS rate than UCB group (P = 0.022). However, 
LFS of M-UD and MM-UD together (65.2%) was not different from that of MRD group 
(76.7%, P = 0.325), or from that of UCB (45.5%, P = 0.190). The relapse incidence at 
5 yr was 17.1%, 20.0%, 15.4%, and 0%, respectively (P = 0.460). The 100-day treatment-
related mortality was 2.9%, 20.0%, 7.7%, and 36.4%, respectively (P = 0.011). Despite 
the limitations of small number of patients, unrelated donor transplants including even 
allele-mismatched ones, seem to be as effective in children with leukemia lacking suitable 
relative donors. Also, UCB transplant may serve as another possible option in urgent 
transplants.
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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is a 
potentially curative therapeutic modality for malignant hema-
tologic disorders. The ideal donor for allogeneic HSCT is a hu-
man leukocyte antigen (HLA)-identical sibling. However, only 
30% of all patients who need transplantation have a suitable sib-
ling donor (1). For transplant candidates lacking an HLA-iden-
tical relative, the choice of the best donor is important but often 
difficult for pediatric patients.
  Alternative donors as a candidate for stem cell sources are vol-
unteer unrelated donors (UDs), unrelated umbilical cord blood 
(UCB), and haplotype-mismatched family members (1, 2). 
  To maximize posttransplant survival in unrelated transplant 
settings, high-resolution matching for HLA is recommended in 
recent studies (3-5). The most important HLA loci influencing 
post-transplant outcome are known to be HLA-A, -B, -C (class I 
loci) and -DRB1 (class II locus) (3, 4). However, the role of other 
class II loci (namely DQB1 and DP1 loci) remains controversial 
(4, 6). Recently, the National Marrow Donor Program (7) released 
the updated guidelines for the selection of an unrelated HSCT 
donor: Whenever possible, donors who are high-resolution 
matched at these 4 HLA loci should be sought, and if a mismatch 
is unavoidable, a single mismatched (MM)-donor (-A, -B, -C, or 
-DRB1) should be sought.
  UCB has been widely used recently in unrelated transplant 
settings because of ready availability, less probability of viral 
contamination and lack of risk to a donor (8). Moreover, UCB is 
known to be associated with less graft versus host disease (GvHD) 
due to naive nature of the lymphocytes displaying a lower allo-
reactive potential than bone marrow (BM) or peripheral blood 
lymphocytes. Thus, less restriction in HLA matching (4-6/6 HLA) 
is required for transplantation (8). However, the most important 
factor influencing the patient outcome in UCB transplantation 
is infused cell dose, as a unit of cord blood has limited cell num-
bers. The cell dose per Kg of recipient body weight, expressed 
either as total nucleated cells or number of CD34+ cells, has a 
significant correlation with engraftment, adverse transplant-re-
lated events and survival (9-11). 
  The selection of unrelated UCB units has been based on the 
number of cells cryopreserved in the unit and HLA data, usual-
ly typed for HLA-A and -B by serology or low-resolution meth-Baek HJ, et al.  •  Alternative Donor Transplants in Children with Leukemia 
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od, and DRB1 by allele typing (12). Selection of cord blood units 
with no more than two HLA disparities and with cell numbers 
more than 3 × 10
7/kg before thawing and 2 × 10
7/kg after thaw-
ing is recommended (11, 13). Recently, double UCB transplan-
tations or expanded UCB have been explored to overcome the 
cell dose limitation (14).
  Several clinical studies, both in adults and children, have 
demonstrated comparable outcomes in respect to engraftment, 
GvHD, and survival between UD bone marrow transplantation 
(BMT) and UCB transplants despite higher HLA disparity in the 
latter group (15-22). The excessive mortality from delayed en-
graftment and graft failure in UCB transplants might be balanced 
by lower mortality from other causes, including GvHD (23). To 
date, however, there have been no prospective studies that com-
pare unrelated BMT with UCB transplants.
  The aim of this retrospective study was to compare the clini-
cal outcomes of allele-matched (M)-unrelated donor (UD) or 
-mismatched (MM)-UD transplantation and those of unrelated 
UCB and to help select the best alternative donor in children with 
leukemia. A comparison with matched related donor (MRD) 
transplantation was also made. 
MATERIALS AND METHODS
Patients
A total of 83 children with leukemia less than 18 years of age un-
derwent allogeneic HSCT at the Chonnam National University 
Hospital and Chonnam National University Hwasun Hospital 
between January 1996 and July 2009. The patients’ medical re-
cords were retrospectively reviewed and analyzed as of June 2011. 
Patients were excluded if they were recipients of double UCB 
transplants (n = 4), UD grafts without HLA typing at allele-levels 
who were transplanted prior to June 2004 (n = 8), or haploiden-
tical-related HSCT (n = 1). An extremely rare case of leukemia, 
CD52+ prolymphocytic leukemia was also excluded. For pa-
tients who underwent 2 allogeneic HSCTs, data of initial trans-
plant were included (n = 5). Also, patients who received an ini-
tial autologous transplant followed by an allogeneic HSCT, only 
the data of allogeneic HSCT was analyzed (n = 2). For transplant 
candidates lacking an HLA-identical relative, M-UDs were sear-
ched. If not available, either MM-UD or UCB was chosen based 
on clinical urgency, cell dose of cord blood unit and HLA dis-
parity.
  Sixty-nine pediatric patients were the subjects for the analyses. 
Among them, 35 patients received HSCT from MRDs, 23 pa-
tients from UDs, and 11 from unrelated UCB (Table 1). 
  Patients were not considered to be evaluable for chronic GvHD 
if they died before 100-day posttransplant. Disease status was 
assessed immediately prior to transplantation, and at Day+28 
and 3 months posttransplant. Patients were subsequently eval-
uated at least every 3 months in the first year, every 6 months in 
the second year, and yearly thereafter.
Donors and HLA-typing
The patients were divided into 4 groups according to the donor 
type: MRD, M-UD, MM-UD and UCB group. HLA typing was 
done by the best available methods at the time of transplanta-
tion. Patients who received an HSCT prior to September 2002 
were typed for HLA-A, and -B by serologic techniques (24) and 
for -DRB1 by intermediate-resolution molecular techniques (25). 
Thereafter, high-resolution DNA typing was used for HLA-A, -B, 
-DRB1 at allele levels. Since June 2004, HLA-C matching has 
been included. All MM-UDs were accepted for transplantation 
only when they were 6/6 matched at antigen levels (HLA-A, -B, 
and DRB1) by serology, but incompatible at allele levels. All cord-
blood units were HLA-typed at antigen levels for HLA-A and -B, 
and DRB1 at respective cord blood bank.
 
Conditioning
As the conditioning for transplant, total body irradiation (TBI)-
based regimens were used in 37 patients, non-TBI regimens in 
28, and reduced intensity conditioning (RIC) in 4. There was no 
significant difference in conditioning regimen among 4 groups. 
  A preparative regimen consisting TBI plus cyclophosphamide 
(CY) with or without cytarabine was used in the majority (80.6%) 
of patients with acute lymphoblastic leukemia (ALL, n = 36). The 
non-TBI regimen of busulfan (BU)/CY was used in 16 patients 
(72.7%) with acute myeloid leukemia (AML, n = 22). The RIC 
consisting of fludarabine/BU/antithymocyte globulin was given 
to each one patient from each group, respectively (Fanconi ane-
mia with AML, secondary AML, relapsed ALL from lympho-
blastic lymphoma, and AML in second remission after previous 
autologous peripheral blood stem cell transplantation, respec-
tively). 
Supportive care
The patients were kept in laminar airflow rooms. To prevent in-
fections, all patients received prophylactic acyclovir, and itra-
conazole or fluconazole. All patients received granulocyte-col-
ony stimulating factor (G-CSF) support from day 0. Transfusion 
support was provided with irradiated blood products. Stem cells 
were infused through a central venous catheter on day 0. 
Definition of terminology
Disease status at transplantation was divided as standard and 
high risk groups: Standard risk: AML in first complete remis-
sion (CR), ALL in first or second CR and chronic leukemia in 
first chronic phase; High risk: more advanced status than stan-
dard risk leukemia or second stem cell transplantation (26, 27).
  Diagnosis and clinical grading of acute and chronic GvHD 
were made according to the established criteria (28). Treatment-
related mortality (TRM) was defined as death during a continu-Baek HJ, et al.  •  Alternative Donor Transplants in Children with Leukemia 
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ous remission from any cause other than relapse. Leukemic-free 
survival (LFS) was defined as survival without relapse or death 
by any cause.
Statistical analysis
Overall survival (OS) and LFS were calculated using the Kaplan-
Meier method. The log-rank test was used for group compari-
sons. Data for patients alive and in continuous remission were 
censored at the time of last follow-up. LFS was calculated from 
the beginning of transplant until relapse or death. The cumula-
tive incidences of relapse, TRM and GvHD were estimated by 
treating deaths as competing risk. Gray’s method was used for 
group comparison of cumulative incidence (29).
  Patient and transplant characteristics were compared across 
donor type subgroups. Statistical comparison of continuous 
variables was performed by the Kruskal-Wallis test or ANOVA. 
Differences in categorical factors were tested across subgroups 
by the use of the chi-square test or Fisher’s exact test. P values 
< 0.05 were considered as statistically significant. Analyses were 
performed using the SPSS software (Statistical Package for the 
Social Science, version 18.0, SPSS Inc, Chicago, IL, USA) and R 
soft ware (version 2.13.0).
Ethics statement
The present study was approved by the Institutional Review 
Board of the Chonnam National University Hwasun Hospital 
(IRB No. 2011-35). A written informed consent was obtained 
from each patient’s guardian.
RESULTS
Patient characteristics
Patients’ clinical characteristics and transplant details across 
the 4 donor groups are shown in Table 1. The numbers of trans-
Table 1. Patients’ clinical and transplantation characteristics
Parameters MRD (n = 35) (%) M-UD (n = 10) (%) MM-UD (n = 13) (%) UCB (n = 11) (%) P value
Age, median
   Recipient (yr)
 
10.5 (1.1-18.6)
 
  9.1 (0.7-16.6)
 
  8.7 (1.3-14.2)
 
  6.3 (0.6-15.0) 0.307 
Disease, No. (%)
   ALL
   AML
   Mixed phenotype leukemia
   Chronic leukemia
 
14 (40.0)
14 (40.0)
2 (7.6)
  5 (14.3)
 
6 (60.0)
1 (10.0)
2 (20.0)
1 (10.0)
 
  8 (61.5)
  4 (30.8)
0
1 (7.7)
 
  8 (72.7)
  3 (27.3)
0
0
0.686
Median follow-up months after transplant (range) 67.0 (1.0-179.0) 36.0 (0.7-83.0) 43.0 (1.7-83.0)   9.0 (0.3-106.0) 0.002
Disease status at transplantation*
   Standard risk
   High risk
 
33 (94.3)
2 (5.7)
 
9 (90.0)
1 (10.0)
 
  13 (100.0)
0
  8 (72.7)
  3 (27.3)
0.547
Conditioning
   TBI regimen
   Non-TBI regimen
   RIC
 
17 (48.6)
17 (48.6)
1 (2.9)
 
4 (40.0)
5 (50.0)
1 (10.0)
 
  8 (61.5)
  4 (30.8)
1 (7.7)
 
  8 (72.7)
  2 (18.2)
1 (9.1)
0.548
GvHD prophylaxis
   CsA/MTX
   Tacrolimus/MTX
   CsA only
   Tacrolimus/MMF
   MTX only
   No
 
28 (80.0)
  0
2 (5.7)
  0
  4 (11.4)
  1
 
2 (20.0)
8 (80.0)
0
0
0
0
 
1 (7.6)
12 (92.3)
0
0
0
0
 
0
0
  9 (81.8)
  2 (18.2)
0
0
0.000
HLA disparity, No. (%)
   Serological match
   1 antigen mismatch
   2 antigen mismatch
   8/8 allele match
   1 allele mismatch
   2 alleles mismatch
   3 alleles mismach
 
  35 (100.0)
  0
  0
35
  0
  0
  0
 
10 (100.0)
0
0
10 (100.0)
0
0
0
 
  6 (46.2)
  7 (53.8)
0
0
  7 (53.8)
  5 (38.5)
1 (7.7)
 
1 (9.1)
  9 (81.8)
1 (9.1)
ND
ND
ND
ND
Stem cell source and numbers, median (range)
   BM/PBSC/CB
   TCC ( × 10
8/kg) 
   MNC ( × 10
8/kg) 
   CD34+ ( × 10
6/kg) 
 
33/2/0
  5.8 (1.4-115.0)
5.6 (1.5-81.0)
6.0 (0.6-89.0)
 
6/4/0
  6.2 (1.6-12.2)
  4.6 (0.9-11.6)
  7.1 (0.6-14.3)
 
8/5/0
  4.1 (1.8-14.8)
  3.0 (1.7-14.3)
  5.5 (2.8-11.0)
 
0/0/11
0.50 (0.15-1.20)
-
0.19 (0.07-0.73)
 
0.634
0.968
†
 0.863
†
 0.451
†
*Standard risk is AML in 1st complete remission (CR), ALL in 1st or 2nd CR and chronic leukemia in 1st chronic phase. High risk is more advanced status than standard risk 
leukemia or 2nd stem cell transplantation; BM, bone marrow; PBSC, peripheral blood stem cell; CB, cord blood; TCC, total nucleated cell; MNC, mononuclear cell; Chronic leu-
kemia including chronic myeloid leukemia (n = 6) and chronic eosinophilic leukemia (n = 1); 
†M-URD vs MM-URD vs MRD. MRD, matched related donor; M-UD, matched unre-
lated donor; MM-UD, mismatched unrelated donor; UCB, umbilical cord blood; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; TBI, total body irradiation; RIC, 
reduced intensity conditioning; CsA, cyclosporine; MTX, methotrexate; MMF, mycophenolate mofetil; ND, not done.Baek HJ, et al.  •  Alternative Donor Transplants in Children with Leukemia 
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Fig. 1. Probability of Kaplan-Meier 5-yr overall survival (A) and leukemic-free survival (B) by different donor groups.
plants by each donor type were as follows: MRD, 35; M-UD, 10; 
MM-UD, 13; and UCB, 11. All the MM-UD patients were matched 
at 6/6 antigens (HLA-A, -B, and -DRB1) by serology, but 7 had 
mismatches in HLA-C. By allele typing of 8 antigens, one locus 
was mismatched in 7 patients, two loci in 5, and three loci in 1. 
In UCB group, only one patient was full matched, and the re-
maining 10 patients were antigen-mismatched (1 antigen MM 
in 9; 2 antigen MM in 1). 
  There were no significant differences in age at transplanta-
tion, disease type, disease status at transplantation and condi-
tioning regimen between the 4 groups. The proportion of high 
risk patients was higher in UCB group (27.3%) than other groups, 
but it was not significant. The median follow-up duration after 
transplant was longer in MRD group (67.0 months) than in oth-
er groups (P = 0.002), as unrelated transplants were more com-
monly applied recently. Also, median follow-up duration after 
transplant was the shortest (9 months) in UCB group as six pa-
tients died prior to 9 months after transplant but the median 
follow-up was 90.0 (75.0-106.0) months in the remaining UCB 
patients.
  GvHD prophylactic regimens were quite different across the 
4 donor groups. Cyclosporine (CyA) plus short-course metho-
trexate (MTX) were used in the majority of MRD group (80.0%), 
while tacrolimus was substituted for CyA in M-UD (80.0%) and 
MM-UD groups (92.3%). CyA alone was used in most of UCB 
group (81.8%). 
Stem cell properties and engraftment kinetics 
The BM was the most frequent source of stem cells (n = 47, 68.1%). 
The proportion was especially higher in MRD grafts (97.3%) than 
that in M-UD (60.0%) or MM-UD (61.5%) transplants (Table 1). 
  There were no significant differences in infused total nucle-
ated cells (TNC), mononuclear cells and CD34 cell counts among 
the 3 groups except for UCB group, which contained one-log 
smaller amount of TNCs. However, only 3 patients were infused 
less than TNC 3 × 10
7/kg of recipient body weight. CD34+ cell 
numbers in UCB group were even lower than 1/10 of other groups. 
  Engraftment failure was not observed. The speed of neutro-
phil and platelet recovery was different according to the donor 
type. The median day to absolute neutrophil counts ≥ 500/μL 
was 15 in MRD, 16 in M-UD, 18 in MM-UD, and 21 in UCB, re-
spectively (P = 0.01). The median day to platelets  ≥ 20,000/μL 
without transfusion for 7 consecutive days was 19 in MRD, 23  
in M-UD, 30 in MM-UD, and 45 in UCB, respectively (P < 0.01). 
Among alternative donor groups, UCB group showed slower re-
covery of both neutrophils and platelets than M-UD group (P =  
0.008, P = 0.001, respectively), or MM-UD group (P = 0.051, P =  
0.01, respectively).
  The engraftment speed between M- or MM-UD group and 
MRD group, or between M- and MM-UD groups was not differ-
ent. 
Acute and chronic GvHD
The cumulative incidence of grade II-IV acute GvHD was signif-
icantly higher in UCB group: 11.8% (n = 4) for MRD, 30.0% (n =  
3) for M-UD, 15.4% (n = 2) for MM-UD, and 54.4% (n = 6) for 
UCB (P = 0.004). 
  Chronic GvHD developed in 14 of 61 evaluable patients (22.9 
%). Six patients had extensive diseases. The cumulative inci-
dence of chronic GvHD was not significantly different between 
the groups (P = 0.523); 18.3% (No./evaluable patients, 5/34) for 
MRD, 27.1% (3/8) for M-UD, 33.3% (4/12) for MM-UD, and 28.6% 
(2/7) for UCB. 
  The incidence of extensive type chronic GvHD was higher in 
MM-UD group than MRD group (P = 0.029). In UCB group, all 
2 patients with chronic GvHD had extensive diseases. Each one Baek HJ, et al.  •  Alternative Donor Transplants in Children with Leukemia 
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from MM-UD and UCB group died of chronic GvHD. 
Overall survival and leukemia-free survival 
The Kaplan-Meier 5-yr OS by donor group was the best in MRD 
group (76.8%), followed by MM-UD (69.2%), M-UD (60.0%) and 
UCB (45.5%) group (P = 0.094) (Fig. 1A). The Kaplan-Meier 5-yr 
LFS showed the same tendency: MRD (76.7%) MM-UD (69.2%), 
M-UD (60.0%), and UCB (45.5%), respectively (P = 0.128) (Fig. 
1B). MRD group showed higher OS and LFS rate than UCB group 
(P = 0.015, P = 0.022. respectively). However, Kaplan-Meier sur-
vival rates (OS, 65.2%; LFS, 65.2%) of all UD groups together (M- 
and MM-) were not different from those of MRD group (OS, 
76.8%, P = 0.288; LFS, 76.7%, P = 0.325), and also from those of 
UCB group (OS, 45.5%, P = 0.179; LFS, 45.5%, P = 0.190), respec-
tively. 
Relapse 
Eleven patients relapsed at the median of 6.0 (2.0-31.0) months 
post-transplantation. All the patients who relapsed died of pro-
gressive disease. Most relapses occurred within the first year 
posttransplant with only one patient relapsing after one year 
and none after 3 yr.
  The cumulative incidence of relapse at 5 yr was not different 
by donor groups: 17.1% for MRD; 20% for M-UD; 15.4% for MM-
UD; and 0% for UCB (P = 0.460). Of note is that there was no re-
lapse case in UCB group. Although none of 7 patients who had 
grade III-IV acute GvHD relapsed, acute GvHD was not associ-
ated with decreased relapse rate (8.3% vs 20.3%, P = 0.391). Also, 
chronic GvHD was not associated with decreased relapse rate 
(8.3% vs 21.6%, P = 0.252).
Treatment-related mortality and cause of death
Eleven patients died of treatment-related causes. All the cases of 
early deaths before 100 days (n = 8) were TRM: GvHD, 1; veno-
occlusive disease, 2; interstitial pneumonia, 3; infection, 1; and 
massive hemorrhage, 1. The cumulative incidence of 100-day 
TRM was higher in UCB group than in other groups: 2.9% for 
MRD; 20.0% for M-UD; 7.7% for MM-UD; and 36.4% for UCB 
group (P = 0.001). There was no TRM after post-transplant 100 
days in other groups except UCB group. The 5-yr cumulative 
TRM rate showed a significant pattern with the highest in UCB 
(54.4%; P = 0.001). In UCB group, causes of TRM were as fol-
lows: GvHD, 2; veno-occlusive disease, 1: interstitial pneumo-
nitis, 2; and infection, 1. Fourteen patients died after 100 days 
posttransplant. Leukemia relapse (n = 11, 78.6%) was the lead-
ing cause of late death, followed by GvHD (n = 2) and infection 
(n = 1). 
DISCUSSION
The HSCT has been the primary treatment modality and the cu-
rative option for certain childhood leukemia, such as high risk 
ALL, most of AML, and relapsed leukemia (26, 27). MRD trans-
plantation is usually preferred, with the LFS rate being 32%-65% 
in high-risk childhood ALL and 60%-70% in childhood AML 
(26, 27). Alternative donors for patients without an HLA-identi-
cal relative are UD, unrelated UCB and haploidentical family 
donors (1, 2). Each alternative donor has advantages and limi-
tations, which should be considered in choosing the best possi-
ble donor.  
  Recently, a meta-analysis of pooled data on comparative stud-
ies of UCBT and UBMT was published which comprised all pa-
tients requiring HSCTs (17). There was no difference in 2-yr OS 
between UCBT and 6/6 antigen matched UBMT in children. On 
behalf of the Center of the International Bone Marrow Registry 
(CIBMTR) and the New York Cord Blood Program, Eapen et al. 
(18) reported comparative results on more restricted popula-
tion of acute leukemia less than 16 yr. Outcomes of 503 children 
transplanted with UCB were compared with 8/8 allele-M BMT 
(n = 116) and 1 or 2 allele-MM BMT (n = 166). Of UCBTs, 35 
were matched at the HLA-A, -B (antigen level) and -DRB1 (al-
lele level) and 201 mismatched at one locus and 267 mismatched 
at two loci. The 5-yr probabilities of LFS for 1-antigen MM UCB 
with a cell dose greater than 3 × 10
7 nucleated cells/kg (45%) and 
1-antigen MM UCB with low cell dose (36%), and 2-MM UCB 
(33%) were similar to M-UD (38%). Smith et al. (30) reported 
transplantation outcome of children with ALL in CR2 by the type 
of available donors. The LFS at 5 yr was lower in recipients of 
MM-UD grafts, but was comparable in all other groups (MSD, 
41%; M-UD, 57%; MM-UD, 19%; UCB, 43%, respectively P =  
0.05). In a recent Korean report on 56 children with acute leu-
kemia the LFS was 57.1% in UCB transplants, which was com-
parable to 63.2% in UD BMT (19).
  In the present study, the Kaplan-Meier 5-yr LFS by donor 
group was the best in MRD group (76.7%), followed by MM-UD 
(69.2%), M-UD (60.0%) and UCB (45.5%) group (P = 0.128). Al-
though UCB showed the lowest survival rate, it was not statisti-
cally different from that of M- or MM-UD. Moreover, 5-yr LFS 
rate of UCB group in our study (45.5%) was not inferior to the 
survival rate of other reports: 45% from 1-antigen MM UCB with 
high cell dose, or 33% from 2-antigen MM UCB from CIBMTR 
and New York Cord Blood Program (18); 43% from University of 
Minnesota (16); 31% 2-yr LFS from Eurocord (15); or 57.1% from 
Korean study (19). 
  As reported in other studies (15-19), the engraftment was 
slower in UCB group than UD groups in this study. However, 
graft failure was not observed despite three patients received 
TNCs less than 3 × 10
7/kg of recipient body weight. 
  Some UCB studies reported that more than 2-antigen MM in-
creased acute GvHD compared with full matching (13) but HLA 
matching did not impact chronic GvHD (18). Another study (17) 
reported that the incidence of chronic GvHD was lower with Baek HJ, et al.  •  Alternative Donor Transplants in Children with Leukemia 
http://jkms.org   1553 http://dx.doi.org/10.3346/jkms.2011.26.12.1548
UCBT (relative risk [RR] = 0.26; P = 0.16), but the incidence of 
grade III-IV acute GvHD did not differ (RR = 1.46; P = 0.55). Our 
results show that the incidence of grade II-IV acute GvHD was 
significantly higher in UCB group (54.4%) than other groups (P =  
0.004). The incidence in our study was higher than that from the 
Eurocord (35.8%) (13). The discrepancy might be HLA-DRB1 
mismatch at allele level because allele level data was not avail-
able in our study. Also, the use of CsA alone as GvHD prophy-
laxis in most of UCB group (81.8%) might be associated with 
higher incidence of acute GvHD in our study. But, chronic GvHD 
did not significantly differ in the 4 groups, although the incidence 
was the lowest in MRD group. 
  Eapen et al. (18) reported the higher TRM rates in 1- and 2- 
antigen MM-UCB was counterbalanced by the lower relapse 
rates. Thus, LFS was not statistically different from 1 or 2 antigen 
MM CBT compared with M-UD BMT. Our 5-yr non-relapse mor-
tality rate (54.4%; P = 0.001) and the 100-day TRM rate (36.4%; 
P = 0.001) was highest in UCB group, which was consistent with 
other reports (15-19). Most relapses occurred within the first 
year posttransplant. The relapse rates were similar among M- 
UD and MM-UD and MRD groups (P = 0.53). Although no re-
lapse occurred in the UCB group, the true relapse rate should 
be analyzed in large series of patients. As previous reports, even 
if our UCB group showed the lowest survival rate, it was not sta-
tistically different from that of other groups.
  In UD transplants, the level of HLA mismatching has an im-
pact on the development of GvHD and survival (4-6). On behalf 
of the CIBMTR, Lee et al. (4) suggested that single mismatches 
at HLA-B or HLA-C appear to be better tolerated than mismatch-
es at HLA-A or HLA-DRB1. Mismatching at HLA-DQ and HLA-
DP did not influence the outcome in large series of UD BMT (3, 
5). Thus, it is usually recommended that high-resolution 4 loci 
of HLA-A, -B, -C, and -DRB1 be typed for the selection of UD 
for transplant (3-5). In our study, all the MM-UD patients were 
matched at 6/6 antigens (HLA-A, -B, and -DRB1) by serology, 
but 7 had mismatches in HLA-C at antigen levels. By allele typ-
ing, 1 locus mismatching was found in 7 patients and 2 more 
loci were mismatched in 6. However, OS rate, relapse rate and 
TRM rate were not significantly different between M-UD and 
MM-UD groups in this small series of patients.
  The authors have summarized the transplant results at a sin-
gle center comparing transplant outcomes by different stem cell 
donor sources for children with leukemia. The 5-yr Kaplan-Mei-
er OS was not different between the 4 groups, although MRD 
group showed the best, while UCB group being the worst (P =  
0.013). However, among the alternative groups other than MRD 
group, the OS rate of UD group, either M- or MM-, was not dif-
ferent from that of UCB group (P = 0.153). Although no relapse 
was found in UCB group, the benefit was offset by the high TRM 
early posttransplant. However, the 5-yr LFS in our UCB group 
(45.5%) was not inferior to that from other reports. 
  In conclusion, despite the limitations of small number of pa-
tients from a single institution, our results suggest that UD trans-
plants, even allele-MM, are effective treatment modality in chil-
dren with leukemia lacking suitable relative donor. Also, UCB 
transplant may also serve as another possible option in urgent 
transplants. These results may justify the simultaneous search 
of unrelated BM donors and unrelated UCB units when a child 
with acute leukemia is in need of an alternative transplant. 
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AUTHOR SUMMARY
Hematopoietic Stem Cell Transplantation in Children with Leukemia: A Single 
Institution Experience with Respect to Donors
Hee Jo Baek, Hoon Kook, Dong Kyun Han and Tai Ju Hwang
We compared the outcomes of transplantation according to the donor source for  children with leukemia. The matched related 
donor (MRD) group showed higher overall survival and leukemia-free survival (LFS) rate than the umblical cord blood (UCB) group. 
However, the LFS of allele-matched (M)-unrelated donor (UD) or -mismatched (MM)-UD groups together was not different from 
that of MRD group, or from that of UCB. Moreover, 5-yr LFS rate of the UCB group was consistent with the findings of other 
reports. UD transplants including even allele- MM ones, seem to be as effective in children with leukemia lacking suitable relative 
donors. Also, UCB transplant may serve as another possible option in urgent transplants.